Maybe it will be. But that's typically something that, you know, you got to plan for all these contingencies. The second thing I've said is, you know, If there is a safe and effective vaccine, I think that the most vulnerable population should have priority. It should be the people who are 65 and older. It should be people that have serious comorbidities, and they should have the priority. And so I don't know how many that would end up being produced. I know they basically paid all these companies already so that they could just go ahead and roll with it as the trials are going. (21:20–21:37)
CLAIM
Asserts that the most vulnerable populations, including those 65 and older and with serious comorbidities, should have priority for a vaccine.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
